Q3 EPS Estimates for DENTSPLY SIRONA Reduced by Analyst

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Equities research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for DENTSPLY SIRONA in a research report issued to clients and investors on Thursday, August 7th. Leerink Partnrs analyst M. Cherny now expects that the medical instruments supplier will post earnings of $0.45 per share for the quarter, down from their prior estimate of $0.46. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Leerink Partnrs also issued estimates for DENTSPLY SIRONA’s Q4 2025 earnings at $0.48 EPS, FY2027 earnings at $2.34 EPS and FY2028 earnings at $2.64 EPS.

XRAY has been the subject of a number of other research reports. Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a report on Monday, July 21st. Barrington Research set a $18.00 price objective on shares of DENTSPLY SIRONA and gave the stock an “outperform” rating in a research note on Friday. Wall Street Zen downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Saturday. Morgan Stanley downgraded shares of DENTSPLY SIRONA from an “overweight” rating to an “equal weight” rating and set a $14.00 price objective for the company. in a research note on Tuesday, April 15th. Finally, Piper Sandler reduced their price objective on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, DENTSPLY SIRONA currently has a consensus rating of “Hold” and a consensus price target of $18.64.

DENTSPLY SIRONA Stock Down 3.4%

Shares of NASDAQ XRAY opened at $12.52 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.11 and a current ratio of 1.69. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -2.64, a PEG ratio of 0.80 and a beta of 0.94. The stock has a 50 day moving average price of $15.64 and a 200 day moving average price of $15.82. DENTSPLY SIRONA has a 52-week low of $12.16 and a 52-week high of $27.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. The firm had revenue of $936.00 million during the quarter, compared to analyst estimates of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%. DENTSPLY SIRONA’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.49 earnings per share.

DENTSPLY SIRONA Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 10th. Stockholders of record on Friday, September 26th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 5.1%. DENTSPLY SIRONA’s dividend payout ratio is presently -13.50%.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of DENTSPLY SIRONA by 2.8% during the first quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier’s stock worth $309,864,000 after purchasing an additional 557,329 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of DENTSPLY SIRONA by 11.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier’s stock worth $208,590,000 after purchasing an additional 1,412,517 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its position in shares of DENTSPLY SIRONA by 4.7% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier’s stock worth $180,445,000 after purchasing an additional 538,531 shares in the last quarter. Lazard Asset Management LLC increased its position in shares of DENTSPLY SIRONA by 23.0% during the fourth quarter. Lazard Asset Management LLC now owns 8,044,228 shares of the medical instruments supplier’s stock worth $152,678,000 after purchasing an additional 1,505,928 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of DENTSPLY SIRONA by 21.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 6,851,869 shares of the medical instruments supplier’s stock worth $130,045,000 after purchasing an additional 1,230,944 shares in the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.